Treatment With Radium-223 and Chemotherapy for Prostate Cancer
Nicholas J. Vogelzang, MD, from the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Nicholas J. Vogelzang, MD, member of the US Oncology Network, site research leader for Comprehensive Cancer Centers of Nevada, professor of medicine at the University of Nevada School of Medicine, gives an overview of combining radium-223 with other agents for the treatment of prostate cancer.
Clinical Pearls
Vogelzang says he and his colleagues believe that radium-223 can be combined safely with all hormonal and immune therapies. In one study, radium-223 was given with chemotherapy and researchers found that less chemotherapy had to be administered. Currently, Vogelzang notes, the FDA recommends that radium-223 should not be given with chemotherapy.
- The oncology community believes that radium-223 can be combined safely with all hormonal and immune therapies
- When given with radium-223, chemotherapy has to be given in a smaller amount
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
